Novo Nordisk Says FDA Accepts Filing Application For oral semaglutide 25 mg
View all comments(0)
May 2 (Reuters) - Novo Nordisk A/S NOVOb.CO:
FDA ACCEPTS FILING APPLICATION FOR ORAL SEMAGLUTIDE 25 MG, WHICH IF APPROVED, WOULD BE THE FIRST ORAL GLP-1 TREATMENT FOR OBESITY
NOVO NORDISK -FDA ACTION DATE TO DECIDE ON WEGOVY(®) ORAL FORMULATION NDA WILL BE IN Q4 2025
Further company coverage: [NOVOb.CO]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.